Vδ2-T cells derived exosomes for tumor immunotherapy


The invention is about a potential therapeutic approach for cancers. The exosomes derived from Vδ2-T cellsnot only directly kill tumor cells but also indirectly inhibit tumor development and progression by enhancing T cell–mediated antitumor activities, which offers great possibility to overcome the shortcomings of conventional immunotherapies for tumors as a cell-free therapy.

  • Vδ2-T cells derived exosomes for tumor immunotherapy
Commercialisation opportunities
Licensing, collaboration and investment
Problem addressed

Current treatment options for EBV-associated cancers are very limited with remarkable unwanted off-target toxicities and incompletely effective for relapsed or refractory diseases. Novel cell-based immunotherapy may be able to inhibit tumor growth; however, could be seriously impeded due to the immunosuppressive tumor microenvironment, and may also create safety issues.

  • Novel immunotherapeutic approach against tumors including solid tumors
Key impact
  • Compared with cell-based immunotherapy, exosomes are more stable in long term storage and can be a off-the-shelf product immediately administered into patients after thawed.
  • Better safety profile and resistant to acidic and immunosuppressive tumor microenvironment.
  • Dual antitumor activities (direct killing and inducing T cell immunity)
  • Novel therapeutic for the treatment of cancers


  • PCT Application No. PCT/CN2020/112573
The University of Hong Kong (HKU)

Founded in 1911, The University of Hong Kong (HKU) is the first and oldest institution of higher education in Hong Kong. For over a century, the University has dedicated itself to creating knowledge, providing education, and serving society. Today, HKU has an established worldwide reputation for being a research-led comprehensive University with ten Faculties and a strong commitment to intellectual freedom, liberty and diversity. HKU has a proud record of academic recognition in researches through honours and awards received from both local and international bodies.